View Biocon in terms of core EBITDA as R&D is an integral part of our biz growth: Kiran Mazumdar Shaw

“I just want to emphasise that Biocon Biologics or Biocon as a business must be viewed in terms of core EBITDA and not just on EBITDA because as you know R&D is a very integral part of our business growth which needs to future proof us and therefore, we cannot afford to decrease R&D spending to sustain growth.”